You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Developing a small peptide to control autoimmune inflammation in type diabetes

    SBC: Op-T-Mune, Inc            Topic: NIAID

    Abstract Type Diabetes T D affects an ever growing population While this disease typically has been associated with juveniles the disease in adult populations is rapidly increasing The defining clinical component is insulin loss which occurs because of sustained inflammation in the islets At present there is no means to prevent or reverse insulin loss A major inflammatory pathway in T D ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Pneumococcal pneumonia remains the leading cause of bacterial pneumonia in both children under years of age and adults over years of age The standard preventative therapy is the conjugate vaccine Prevnar which consists of an immunogenic carrier protein covalently attached to one of thirteen pneumococcal capsular polysaccharides Although Prevnar has significantly red ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. ErythroMer Nanoscale Bio Synthetic Red Cell Substitute

    SBC: KaloCyte Inc            Topic: NHLBI

    PROJECT SUMMARY There is need for an artificial oxygen O carrier to substitute for banked blood in settings where stored blood is unavailable pre hospital care transport austere environments undeveloped countries or undesirable transfusion risk exceeds benefit To address this need we developed ErythroMer EM a first in class nano cyte blood substitute EM is a deformable ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Enabling point of care molecular diagnostics by developing an adaptive PCR instrument and on demand kit reagents

    SBC: BIOVENTURES, INC            Topic: 172

    Because of its high sensitivity polymerase chain reaction PCR is the gold standard for the diagnosis of many infectious diseases but generally only implemented in well equipped laboratories One of the major roadblocks for expanding PCR to point of care markets is the lack of simple robust single tube PCR designs which preserve its laboratory based high sensitivity and specificity In this F ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. E training of Inmate Peer Caregivers for Enhancing Geriatric and End of life Care in Prisons

    SBC: KLEIN BUENDEL, INC.            Topic: NIA

    The US has the highest incarceration rate in the world imprisoning people per The older adult segment of the prison population has more than tripled since and their health issues are common to free people who are years their senior Inmates over the age of have a death rate that is times that of prisoners aged US prison systems are facing sharply increased dema ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Screening for the autoimmune component of multiple sclerosis

    SBC: Op-T-Mune, Inc            Topic: NIAID

    Multiple Sclerosis is an inflammatory neurodegenerative disease with autoimmune components that exacerbate and potentially initiate the disease Diagnosis is invasive time consuming relatively expensive and extremely difficult In fact no clear diagnostic test yet exist A major concern is that MS symptoms are identical to the symptoms of numerous other neurologic diseases OND as well as some ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Designing and Evaluating Outcome Assessment Software for Youth with Developmental Disabilities: The Pediatric Evaluation of Disability Inventory- Patient Reported Outcome (PEDI-PRO)

    SBC: ABLELINK TECHNOLOGIES INC            Topic: NICHD

    Children and youth with developmental disabilitiesDDreceive extensive pediatric rehabilitation services to address functional limitations in self caremobilityand socializationThe Patient Protection and Affordable Care Act mandates the inclusion of the patient s perspective in healthcare evaluationYetthere is a lack of self reported healthcare assessments appropriate for youth with DDTo accurately ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Non invasive risk assessment tool for pediatric heart failure

    SBC: CORAMIR BIOMEDICAL, INC.            Topic: NHLBI

    ABSTRACT Heart Failure HF in pediatric patients is a devastating disease that is difficult to evaluate even with invasive hospital procedures Importantly and unique to the pediatric population approximately of pediatric HF patients spontaneously recover normal heart function within year of diagnosis Unfortunately there is no reliable clinical parameter or biomarker that allows pedia ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Novel HDAC Inhibitors for Treatment of Hemoglobinopathies

    SBC: CETYA THERAPEUTICS, INC.            Topic: NHLBI

    Project Summary Induction of normal but developmentally silenced fetal globin expression reduces anemia and ameliorates clinical severity in the beta hemoglobinopathies HDACs and are components of the NURD repressor complex which promotes silencing of fetal globin in adult cells Prior generation HDAC inhibitors have increased fetal globin in patients but had limitations for pharmaceu ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Develop a new cisplatin based drug combination with reduced ototoxicity

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIDCD

    PROJECT SUMMARY In spite of recent new drug developments platinum based drugs such as cisplatin are still widely used to treat solid organ malignancies Besides its limited efficacy serious side effects have been associated with the use of cisplatin such as bilateral and irreversible hearing loss In the cochlea cisplatin can trigger the production of reactive oxygen species and activate sev ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government